Chang Ta-Chen, Shirato Hiroki, Aoyama Hidefumi, Ushikoshi Satoshi, Kato Norio, Kuroda Satoshi, Ishikawa Tatsuya, Houkin Kiyohiro, Iwasaki Yoshinobu, Miyasaka Kazuo
Department of Radiology, School of Medicine, Hokkaido University Hospital, North-15 West-7, Sapporo 060-8638, Japan.
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):861-70. doi: 10.1016/j.ijrobp.2004.04.041.
To investigate the appropriateness of the treatment policy of stereotactic irradiation using both hypofractionated stereotactic radiotherapy (HSRT) and stereotactic radiosurgery (SRS) for arteriovenous malformations (AVMs) located in an eloquent region or for large AVMs and using SRS alone for the other AVMs.
Included in this study were 75 AVMs in 72 patients, with a mean follow-up of 52 months. Of the 75 AVMs, 33 were located in eloquent regions or were >2.5 cm in maximal diameter and were given 25-35 Gy (mean, 32.4 Gy) in four daily fractions at a single isocenter if the patient agreed to prolonged wearing of the stereotactic frame for 5 days. The other 42 AVMs were treated with SRS at a dose of 15-25 Gy (mean, 24.1 Gy) at the isocenter. The 75 AVMs were classified according to the Spetzler-Martin grading system; 21, 23, 28, 2, and 1 AVM were Grade I, II, III, IV, V, and VI, respectively.
The overall actuarial rate of obliteration was 43% (95% confidence interval [CI], 30-56%) at 3 years, 72% (95% CI, 58-86%) at 5 years, and 78% (95% CI, 63-93%) at 6 years. The actuarial obliteration rate at 5 years was 79% for the 42 AVMs <2.0 cm and 66% for the 33 AVMs >2 cm. The 5- and 6-year actuarial obliteration rate was 61% (95% CI, 39-83%) and 71% (95% CI, 47-95%), respectively, after HSRT and 81% (95% CI, 66-96%) and 81% (95% CI, 66-96%), respectively, after SRS; the difference was not statistically significant. Radiation-induced necrosis was observed in 4 subjects in the SRS group and 1 subject in the HSRT group. Cyst formation occurred in 3 patients in the SRS group and no patient in the HSRT group. A permanent symptomatic complication was observed in 3 cases (4.2%), and 1 of the 3 was fatal. All 3 patients were in the SRS group. The annual intracranial hemorrhage rate was 5.5-5.6% for all patients.
Our treatment policy using SRS and HSRT was as effective as the policy involving SRS alone. The HSRT schedule was suggested to have a lower frequency of radiation necrosis and cyst formation than the high-dose SRS schedule. The benefit of HSRT compared with lower dose SRS has not yet been determined.
探讨对于位于功能区的动静脉畸形(AVM)或大型AVM采用大分割立体定向放射治疗(HSRT)和立体定向放射外科(SRS)联合的立体定向放射治疗策略,以及对于其他AVM单纯采用SRS治疗策略的合理性。
本研究纳入72例患者的75个AVM,平均随访52个月。75个AVM中,33个位于功能区或最大直径>2.5 cm,如果患者同意延长立体定向框架佩戴时间5天,则在单个等中心分4次每日给予25 - 35 Gy(平均32.4 Gy)。其他42个AVM在等中心接受15 - 25 Gy(平均24.1 Gy)的SRS治疗。75个AVM根据Spetzler - Martin分级系统进行分类;分别有21、23、28、2、1个AVM为I、II、III、IV、V和VI级。
3年时总体闭塞精算率为43%(95%置信区间[CI],30 - 56%),5年时为72%(95% CI,58 - 86%),6年时为78%(95% CI,63 - 93%)。42个直径<2.0 cm的AVM在5年时的闭塞精算率为7�%,33个直径>2 cm的AVM为66%。HSRT后5年和6年的闭塞精算率分别为61%(95% CI,39 - 83%)和71%(95% CI,47 - 95%),SRS后分别为81%(95% CI,66 - 96%)和81%(95% CI,66 - 96%);差异无统计学意义。SRS组4例、HSRT组1例出现放射性坏死。SRS组3例患者出现囊肿形成,HSRT组无患者出现。观察到3例(4.2%)永久性症状性并发症,其中3例中的1例死亡。所有3例患者均在SRS组。所有患者的年颅内出血率为5.5 - 5.6%。
我们采用SRS和HSRT的治疗策略与单纯采用SRS的策略效果相同。与高剂量SRS方案相比,HSRT方案的放射性坏死和囊肿形成发生率较低。与低剂量SRS相比,HSRT的益处尚未确定。